RICHMOND, Va., Oct 24, 2006 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM) announced today the addition of Henry Bunsow as outside counsel to its legal team. Mr. Bunsow was recently named one of the top 25 patent attorneys in California.
Henry Bunsow is the Managing Partner of the Northern California offices of Howrey Simon Arnold & White, LLP. As Managing Partner, Mr. Bunsow has represented clients before district courts and courts of appeal in intellectual property cases involving various technologies. Joining Mr. Bunsow on Insmed's litigation team are David Bilsker, and Rick Chang.
With over 30 years experience in intellectual property litigation, Mr. Bunsow has tried over 30 cases to verdict or judgment with a 90% win-rate. He has successfully argued numerous appeals before the Court of Appeals for the Federal Circuit. During 2001-2004, he tried and won six jury patent cases, four for the patent owner and two representing the accused infringer. In October of 2002, Mr. Bunsow won one of the top ten intellectual property verdicts that year against Ericsson for infringement of a patent on wireless communications for over $60 million, and a finding of willful infringement.
"We are very pleased to add Henry and his colleagues at Howrey to our existing litigation team and believe they bring a wealth of experience," stated Geoffrey Allan, Ph.D., President and CEO.
About Insmed
Insmed is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.
Forward Looking Statements
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for the purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding the pending litigation and or future ability to conduct our business as now conducted and as it is currently proposed to be conducted. Such forward-looking statements are subject to numerous risks and uncertainties, including but not limited to the uncertainty of the outcome of any litigation with Tercica, the risk that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the company may lack financial resources to complete development of product candidates or the FDA or other regulatory agencies may interpret the results of our studies differently than we have. We can give no assurances that we would be successful in any litigation or that such litigation would not have a material adverse effect on our business, financial condition and results of operation. Furthermore, we may not be able to afford the expense of defending against such a claim. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.
